Navigation Links
Neurologix Announces Second Quarter 2011 Financial Results
Date:8/11/2011

f operations after October 31, 2011 and to repay the promissory notes issued in December 2010 as of said date. Accordingly, there is substantial doubt as to the Company's ability to continue as a going concern. The Company is currently seeking to raise funds, through public or private equity offerings, debt financings or corporate collaboration and licensing arrangements, sufficient to finance its ongoing operations.  The Company does not know whether additional financing will be available when needed, or if available, will be on acceptable or favorable terms to it or its stockholders.
  • The Company will need to conduct future clinical trials for the treatment of Parkinson's disease using the Company's NLX technology. If the trials prove unsuccessful, future operations and the potential for profitability will be materially adversely affected and the business may not succeed.

  • Other factors and assumptions not identified above could also cause the actual results to differ materially from those set forth in the forward-looking statements. Additional information about factors that could cause results to differ materially from management's expectations is found in the section entitled "Risk Factors" in the Company's 2010 Annual Report on Form 10-K. Although the Company believes these assumptions are reasonable, no assurance can be given that they will prove correct. Accordingly, you should not rely upon forward-looking statements as a prediction of actual results. Further, the Company undertakes no obligation to update forward-looking statements after the date they are made or to conform the statements to actual results or changes in the Company's expectations.

    Contact:Neurologix
    Marc Panoff, 201-592-6451
    Chief Financial Officer
    marcpanoff@neurologix.net'/>"/>

    SOURCE Neurologix, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related biology technology :

    1. Neurologix Presents One-Year Follow-Up Data From Phase 2 Study of NLX-P101 in Parkinsons Disease at International Neuromodulation Society 10th World Congress
    2. Bion Announces New U.S. Patent for Phosphorus Removal
    3. ViaCyte Announces Executive Management Changes
    4. NeoStem Announces the Receipt of Over $1,700,000 in DOD Funding for its VSEL™ Technology Being Developed to Treat Osteoporosis
    5. Dendreon Announces Webcast Presentation at Canaccord Genuity Growth Conference
    6. Osteologix Announces Completion of Corporate Consolidation
    7. Interleukin Genetics, Inc. Announces Conference Call to Discuss Second Quarter 2011 Results
    8. Palatin Announces Commencement of a Phase 1 Trial for Obesity Compound in Collaboration with AstraZeneca
    9. Rigel Announces Second Quarter 2011 Financial Results
    10. WAVi Co. Announces Collaborative Agreement with SomaLogic, Inc.
    11. Vermillion Announces Notice of Allowance for Peripheral Artery Disease (PAD) Patent
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/29/2014)... 29, 2014  Pfenex Inc. (NYSE MKT: PFNX), ... of high-value and difficult to manufacture proteins including ... reported financial results for the second quarter ended ... completion of our initial public offering, we have ... product candidates, derived from our proprietary protein expression ...
    (Date:8/29/2014)... on electrons, but one of the most promising technologies ... based on light (photons) instead of electrons. First, it ... of single photons and control their direction. Researchers around ... achieve this control, but now scientists at the Niels ... of photons emitted one at a time and in ...
    (Date:8/29/2014)... (PRWEB) August 29, 2014 The ... $5.6 billion in 2019. It is expected to ... to 2019, and was valued at $1.8 billion ... by Transparency Market Research. , For more information ... http://www.transparencymarketresearch.com/companion-diagnostics-market.html . , The research report, titled “Companion ...
    (Date:8/29/2014)... (PRWEB) August 29, 2014 According to a ... Market” the global orthobiologics market was valued at USD 3,754.6 ... worth USD 5,519.9million in 2019at a CAGR of 5.9% from ... 50 years and above is afflicted by bone and joint ... the year 2020. This has and will continue to increase ...
    Breaking Biology Technology:Pfenex Reports Second Quarter 2014 Results and Provides Business Update 2Pfenex Reports Second Quarter 2014 Results and Provides Business Update 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 4Pfenex Reports Second Quarter 2014 Results and Provides Business Update 5Pfenex Reports Second Quarter 2014 Results and Provides Business Update 6Pfenex Reports Second Quarter 2014 Results and Provides Business Update 7Pfenex Reports Second Quarter 2014 Results and Provides Business Update 8Breakthrough in light sources for new quantum technology 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 3Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 2Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 3
    ... Amarin Corporation plc,(NASDAQ: AMRN ) ("Amarin" or ... of Amarin, will present at the Acumen,BioFin Rodman & ... 12 noon Eastern time. The conference will be held ... New York. The presentation will be simultaneously webcast ...
    ... NeurogesX, Inc.,(Nasdaq: NGSX ), a biopharmaceutical company ... that it is scheduled to present,on Monday, November ... Annual,Healthcare Conference and on Tuesday, November 6, 2007 ... Healthcare Conference. Anthony DiTonno,President and Chief Executive Officer, ...
    ... October 31 Revotar,Biopharmaceuticals AG., today announced first ... IIa pilot study in 14 patients with,stable COPD ... mg of Bimosiamose,twice a day. The study was ... Prof. Witt and the Respiratory Institute Wiesbaden, Dr.,Beeh. ...
    Cached Biology Technology:Amarin Corporation to Present at Acumen BioFin Rodman & Renshaw Ninth Annual Healthcare Conference 2Amarin Corporation to Present at Acumen BioFin Rodman & Renshaw Ninth Annual Healthcare Conference 3NeurogesX to Present at CIBC World Markets 18th Annual Healthcare Conference and Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference 2NeurogesX to Present at CIBC World Markets 18th Annual Healthcare Conference and Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference 3Revotar Reports First Positive Clinical Results From Phase IIa Study in COPD 2
    (Date:8/29/2014)... Researchers at UC Davis have made some surprising ... infection. Studying simian immunodeficiency virus (SIV), the team ... Paneth cells are early responders to viral invasion ... producing a cytokine called interleukin-1 beta (IL-1β). ... IL-1β causes breakdown of the gut epithelium that ...
    (Date:8/29/2014)... (Aug. 29, 2014) Scientists at the Barshop Institute ... of Medicine at the UT Health Science Center at ... the tissues of the longest-lived rodent, the naked mole ... the cells of naked mole rats protects and alters ... damaged and obsolete proteins. , The factor also protects ...
    (Date:8/29/2014)... been known about what genetic changes transform wild animals ... of whom is a University of Montana assistant professor, ... the development of the brain and the nervous system ... published Aug. 28 in Science and gives ... http://www.sciencemag.org/ ., The domestication of animals and plants, ...
    Breaking Biology News(10 mins):The early cost of HIV 2Factor in naked mole rat's cells enhances protein integrity 2New research reveals how wild rabbits were genetically transformed into tame rabbits 2New research reveals how wild rabbits were genetically transformed into tame rabbits 3
    ... too short, then you,re not alone. A team of scientists from Texas ... long life and they made important discoveries that bring longer life spans ... of The FASEB Journal ( http://www.fasebj.org ), describes how scientists ... the process discovered a new metabolic state correlating with long life. ...
    ... of two studies published in the current issue of ... cerebral ischemia and ischemic stroke in rats may significantly ... found that administering bone marrow stromal stem cells (MSC) ... which coincided with activation of microglia and new blood ...
    ... This release is available in German . , ... reliable testing of HIV inhibitors. This system was developed under ... Virology. At the heart of the system are cultured human ... that signal HIV infection by producing a red fluorescent protein. ...
    Cached Biology News:Longevity breakthrough: The metabolic state of mitochondria controls life span 2Stroke research takes 2 steps forward 2Stroke research takes 2 steps forward 3A powerful new technology to identify HIV inhibitors 2
    Request Info...
    ...
    ...
    ... are available in two product models - the ... models is that the 6000AT+ includes a membrane ... aerosol for improved detection limits and reduced oxides. ... range of elements by 10-40 times. Note that ...
    Biology Products: